Introduction: Mycoplasma genitalium, often overlooked in discussions about sexually transmitted infections (STIs), is slowly coming into the spotlight as a significant cause of urogenital diseases. This tiny bacterium, discovered in the 1980s, has been linked to a range of conditions, from urethritis in men to pelvic inflammatory disease in women. This blog post aims to shed light on Mycoplasma genitalium, its symptoms, diagnosis, treatment, and prevention, providing essential information to enhance public awareness and promote sexual health.
Mycoplasma genitalium is a small, slow-growing bacterium that infects the urinary and genital tracts of humans. Its size and lack of a cell wall distinguish it from other bacteria, making it a unique challenge in terms of treatment. Initially identified in the early 1980s, Mycoplasma genitalium has been increasingly recognized as a common sexually transmitted infection, albeit less well-known than chlamydia, gonorrhea, and syphilis.
without knowing it. When symptoms do occur, they can include:
If left untreated, Mycoplasma genitalium can lead to serious reproductive health complications, such as infertility in women and increased risk of HIV transmission.
Diagnosing Mycoplasma genitalium involves nucleic acid amplification tests (NAATs), which can detect the bacterium’s genetic material in urine samples or swabs from the genital area. However, due to its relative obscurity and the specificity of testing required, it is not always included in standard STI screening panels. Individuals experiencing symptoms or those with new or multiple sexual partners should request testing from their healthcare provider.
Preventing Mycoplasma genitalium follows the same guidelines as preventing other STIs:
Treatment of Mycoplasma genitalium can be challenging due to its resistance to many common antibiotics. The current guideline suggests a course of antibiotics, typically starting with azithromycin followed by moxifloxacin if the initial treatment fails. Due to the increasing resistance of Mycoplasma genitalium to antibiotics, it’s crucial for healthcare providers to follow the latest treatment protocols and consider resistance testing when available.